Drug Profile
Eltanexor - Karyopharm Therapeutics
Alternative Names: ATG 016; KPT-8602; ONO-7706Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Karyopharm Therapeutics
- Developer Antengene Corporation; Karyopharm Therapeutics; Rega Institute for Medical Research
- Class Anti-inflammatories; Antineoplastics; Fluorinated hydrocarbons; Pyrimidines; Small molecules; Triazoles
- Mechanism of Action Exportin-1 protein inhibitors; Nuclear export inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Colorectal cancer; Multiple myeloma; Myelodysplastic syndromes; Nasopharyngeal cancer; Prostate cancer; Solid tumours; Squamous cell cancer
- No development reported Acute myeloid leukaemia; Gastric cancer; Inflammatory bowel diseases; Oesophageal cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Triple negative breast cancer
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA (PO)
- 28 Jul 2023 No recent reports of development identified for preclinical development in Precursor-cell-lymphoblastic-leukaemia-lymphoma in Belgium (PO)
- 28 May 2023 No recent reports of development identified for clinical-Phase-Unknown development in Triple-negative-breast-cancer in Unknown (PO)